wire - news in brief
Category
--
Results 401 - 432 of 432.
On September 14, an expedition within the framework of the international project Ice Memory is setting out to carry out ice core drilling on the glacier of the mountain massif Grand Combin in the Swiss canton of Valais.
Process Engineer Adriano Joss from Eawag water research institute has been working for many years on wastewater treatment plants and the removal of micropollutants from water.
The FMI is a partner of the pan-European LifeTime initiative. In two publications, researchers involved with the initiative - including FMI group leader Susan Gasser - present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual's lifetime.
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.
Molecular glue degraders are a new class of drugs that work by facilitating an interaction between a disease-causing target protein and a ubiquitin ligase complex, tagging the target protein for degradation.
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
Two talented young researchers at Empa will be given the opportunity to develop their own research area over a five-year period with the help of an ERC Starting Grant from the European Research Counc
ETH has once again been highly successful in the awarding of this year's ERC Starting Grants for young researchers, with the European Research Council (ERC) approving a total of CHF 21.4 million in funding for 12 ETH project submissions.
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
How the Swiss fared under partial lockdown
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
A joint study by EPFL, the Idiap Research Institute and the University of Lausanne's Institute of Psychology has provided us with a unique snapshot of how Swiss residents experienced the partial lockdown measures resulting from the coronavirus pandemic. The findings include gender disparities, doubts about the future and hopes for change.
Organoid? was launched today. It aims at validating organoids as faithful models of human biology, combining single-cell profiling and organoid technology.
As impressive as they may be, the latest AI systems are still no match for humans. Benjamin Grewe pushes for tomorrow's intelligent machines to learn the way young children do.
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
